Royce & Associates’s OptimizeRx OPRX Stock Holding History

Royce & Associates’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.23M	Buy	1,089,398 +201,368	+23%	+$1.16M	0.05%	468
2026 Q1	$5.58M	Buy	888,030 +206,000	+30%	+$1.91M	0.06%	447
2025 Q4	$8.36M	Buy	682,030 +4,700	+0.7%	+$76.8K	0.08%	363
2025 Q3	$13.9M	Sell	677,330 -113,310	-14%	-$1.8M	0.14%	227
2025 Q2	$10.7M	Sell	790,640 -203,660	-20%	-$2.23M	0.11%	273
2025 Q1	$8.61M	Sell	994,300 -75,260	-7%	-$460K	0.09%	322
2024 Q4	$5.2M	Buy	+1,069,560	New	+$5.98M	0.05%	469
2022 Q3	–	Sell	-44,000	Closed	-$1.21M	–	960
2022 Q2	$1.21M	Hold	44,000	–	–	0.01%	729
2022 Q1	$1.66M	Buy	+44,000	New	+$1.95M	0.01%	745
2021 Q4	–	Sell	-11,450	Closed	-$980K	–	1006
2021 Q3	$980K	Sell	11,450 -13,750	-55%	-$863K	0.01%	821
2021 Q2	$1.56M	Buy	25,200 +800	+3%	+$40.7K	0.01%	794
2021 Q1	$1.19M	Buy	24,400 +1,500	+7%	+$72.4K	0.01%	832
2020 Q4	$714K	Buy	22,900 +2,900	+15%	+$71K	0.01%	850
2020 Q3	$417K	Buy	20,000 +5,100	+34%	+$87.6K	﹤0.01%	877
2020 Q2	$194K	Buy	+14,900	New	+$162K	﹤0.01%	936

Other funds holding OPRX

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

BAM

Bullseye Asset Management Denver, Colorado $197M AUM 20.63% 1-Year Est. Return

Royce & Associates's OPRX Position: Q2 2026 in Review

Royce & Associates increased its OptimizeRx (OPRX) stake by 23% in Q2 2026, buying an estimated $1.16M and bringing the position to 1,089,398 shares worth $6.23M. The position accounts for 0.05% of the portfolio, ranked #468.

Royce & Associates first reported a position in OPRX in Q2 2020 and has held it in 15 quarters since. The position peaked at $13.9M in Q3 2025. 113 funds tracked by Wall St. Rank hold OPRX as of Q2 2026.

Royce & Associates held 1,089,398 shares of OptimizeRx worth $6.23M as of Q2 2026.
Royce & Associates bought 201,368 OptimizeRx shares in Q2 2026, an estimated $1.16M.
OptimizeRx made up 0.05% of Royce & Associates's portfolio in Q2 2026, its #468 holding.
Royce & Associates first reported a position in OptimizeRx in Q2 2020 and has held it in 15 quarters since.
Royce & Associates's OptimizeRx position peaked at $13.9M in Q3 2025.
113 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.